Spinal-fluid gene drug reaches brain and cuts target protein

Credibility

Interest

Share:2 min read

Key Takeaway

A gene-targeting drug given into the spine reached motor areas of the brain and spinal cord and lowered the disease protein there, showing intrathecal delivery can work in human nervous tissue.

What They Found

Researchers studied tissue from eight people who had received tofersen, a drug that binds to a specific disease gene message and helps lower the harmful SOD1 protein. They found the drug spread to the spinal cord and motor cortex in amounts that matched what they expected from how much and how often it was given into the fluid around the spinal cord. In three people who had recently received the drug, levels of the SOD1 gene message and SOD1 protein in the lower spinal cord were 45%–84% lower than in people who had never received the drug. Remaining motor nerve cells showed signs that the drug entered them and that the SOD1 message was reduced. Some people who had recently gotten the drug showed immune cells near the brain and spinal cord coverings and blood vessels, a sign of inflammation that was not seen in people who had their last dose a long time before death.

Who Should Care and Why

MS patients and caregivers should know this study because it shows a drug given into spinal fluid can reach brain and spinal cord tissues—an important proof that this delivery method can work for nervous system conditions. For people with MS, similar delivery routes are sometimes considered for treatments that must get into the brain or spinal cord; this study helps show what to watch for in how the drug spreads. The finding that the target protein was strongly lowered in nerve areas is encouraging for any condition where blocking a bad protein might help, though this study was in a different disease. The observed immune reaction is a reminder that treatments given into the spine can cause inflammation, so monitoring and talking to your care team about symptoms after such treatments is important. Doctors, caregivers, and patients should use this information to weigh benefits and risks if a spinal-fluid delivery treatment is considered, and to plan monitoring for possible inflammation.

Important Considerations

This study looked at only eight people who had a specific genetic form of ALS, not MS, so results may not apply directly to MS treatments. Tissue came from people after death, so it shows where the drug reached and what it did in tissue but doesn’t prove the drug helps patients feel or function better. The immune findings raise safety questions that need larger, live-patient studies to understand how often inflammation happens and what it means for symptoms or long-term safety.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research Clinical Trials MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News